RxDoctor Payments Data

Robert Coppola, DO

Neurology · Miami, FLNPI 1518405463

Payments from drug & device makers

$92,529in general payments, 2019–2025

Across 594 payments — averaging $155.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$43K
  • TG Therapeutics, Inc.$21K
  • E.r. Squibb & Sons, L.L.C.$7K
  • AstraZeneca$6K
  • EMD Serono, Inc.$5K
  • Novartis$1K
  • plus $9K from 36 others
$1,445in research payments, 2019–2025

Across 12 payments — averaging $120.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$1K

What the payments were for

  • Consulting fees$10,97112%
  • Speaking & faculty fees$62,32067%
  • Travel & lodging$1,8932%
  • Food & beverage$17,03818%
  • Education$3070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,529 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$220,211
Medicare patients
350
Services billed
1,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate40$341,718
Kesimpta PenOfatumumab37$313,359
GilenyaFingolimod Hcl14$148,840
ZeposiaOzanimod Hydrochloride13$115,599
ProvigilModafinil11$49,650
Teriflunomide46$31,212
Dalfampridine ErDalfampridine38$28,324
LyricaPregabalin11$5,966
Modafinil38$4,372
Donepezil Hcl328$3,288
Gabapentin141$1,554
Baclofen84$1,521
Memantine Hcl58$1,506
Propranolol Hcl ErPropranolol Hcl34$1,452
Carbidopa-LevodopaCarbidopa/Levodopa78$1,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$43,181$341,71840 claims
NovartisGilenya$1,314$148,84014 claims
E.r. Squibb & Sons, L.L.C.Zeposia$6,593$115,59913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →